Hepatocellular carcinoma (HCC) is the fifth most commonly occurring cancer worldwide.¹ In 2012, there were 782,000 new cases of HCC globally, 83% of which occurred in less developed regions.² Although surgery is currently the most effective treatment for HCC, tumor recurrence rate is very high after tumor resection, and the age-standardized 5-year relative survival rate of HCC is only 10.1%.³ Owing to the difficulty of early diagnosis, most HCC patients are diagnosed at an advanced stage at the initial visit, and lose the opportunity for curative treatment such as hepatectomy or ablation, making HCC the second leading cause of cancer-related death in adult males due to the lack of effective therapies.⁴ Sorafenib and Lenvatinib, the two clinically approved targeted drugs for first-line treatment of patients with unresectable HCC, could extend the overall survival by only 2–3 months.^5,6 Thus, there is an urgent need for new methods of treating HCC.

中文翻译：

---

靶向glypican-3的分裂嵌合抗原受体修饰的T细胞抑制肝细胞癌的生长并减少细胞因子的释放

肝细胞癌（HCC）是全球第五大最常见的癌症。¹ 2012 年，全球新增 HCC 病例 782,000 例，其中 83% 发生在欠发达地区。²虽然手术是目前 HCC 最有效的治疗方法，但肿瘤切除后肿瘤复发率非常高，HCC 年龄标准化 5 年相对生存率仅为 10.1%。³由于早期诊断困难，大多数 HCC 患者在初次就诊时已被诊断为晚期，失去了肝切除或消融等治愈性治疗的机会，使 HCC 成为成年男性癌症相关死亡的第二大原因由于缺乏有效的治疗方法。⁴索拉非尼（Sorafenib）和乐伐替尼（Lenvatinib）这两种临床批准的靶向药物，用于不可切除的 HCC 患者的一线治疗，它们的总生存期仅能延长 2-3 个月。^5,6因此，迫切需要治疗 HCC 的新方法。